{"keywords":["Immunotherapy","lung cancer","nivolumab"],"genes":["NNT-PD-L1 antibody"],"publicationTypes":["Journal Article"],"abstract":"A review and critical consideration of immunotherapeutical concepts in non-small cell lung cancer (NSCLC) is given. Nivolumab represents a promising option in various malignancies with more results exceeding treatment of metastatic malignant melanoma eagerly awaited. ","title":"A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors.","pubmedId":"25806335"}